The introduction of psychedelic therapy into the healthcare system requires the development of a new suite of infrastructure beyond drug development, including education, training, specialized clinics, new EMR tools, and ongoing research to improve outcomes. In this session, we will hear from executives of major psychedelic drug developers are doing to build these foundations during pre-approval stages.